Pfizer tops estimates, hikes low end of revenue guidance on strength of Eliquis, other drugs

<iframe
  src="https://statesidedaily.com/embed/cluster/81145f2e78e31dead3309dc7a53a5e7ab07b5e57"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="Pfizer tops estimates, hikes low end of revenue guidance on strength of Eliquis, other drugs"></iframe>